143 related articles for article (PubMed ID: 9703468)
1. Synthesis and comparison of the antiinflammatory activity of manoalide and cacospongionolide B analogues.
De Rosa M; Giordano S; Scettri A; Sodano G; Soriente A; Pastor PG; Alcaraz MJ; Payá M
J Med Chem; 1998 Aug; 41(17):3232-8. PubMed ID: 9703468
[TBL] [Abstract][Full Text] [Related]
2. Total syntheses of (+)- and (-)-cacospongionolide B, cacospongionolide e, and related analogues. Preliminary study of structural features required for phospholipase a2 inhibition.
Cheung AK; Murelli R; Snapper ML
J Org Chem; 2004 Aug; 69(17):5712-9. PubMed ID: 15307744
[TBL] [Abstract][Full Text] [Related]
3. Manoalide.
Soriente A; De Rosa MM; Scettri A; Sodano G; Terencio MC; Payá M; Alcaraz MJ
Curr Med Chem; 1999 May; 6(5):415-31. PubMed ID: 10101221
[TBL] [Abstract][Full Text] [Related]
4. Petrosaspongiolides M-R: new potent and selective phospholipase A2 inhibitors from the New Caledonian marine sponge Petrosaspongia nigra.
Randazzo A; Debitus C; Minale L; García Pastor P; Alcaraz MJ; Payá M; Gomez-Paloma L
J Nat Prod; 1998 May; 61(5):571-5. PubMed ID: 9599251
[TBL] [Abstract][Full Text] [Related]
5. Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2.
García Pastor P; De Rosa S; De Giulio A; Payá M; Alcaraz MJ
Br J Pharmacol; 1999 Jan; 126(1):301-11. PubMed ID: 10051149
[TBL] [Abstract][Full Text] [Related]
6. Conformationally restricted (+)-cacospongionolide B analogues. Influence on secretory phospholipase A2 inhibition.
Murelli RP; Cheung AK; Snapper ML
J Org Chem; 2007 Mar; 72(5):1545-52. PubMed ID: 17315974
[TBL] [Abstract][Full Text] [Related]
7. Total syntheses of (+)- and (-)-cacospongionolide B: new insight into structural requirements for phospholipase A(2) inhibition.
Cheung AK; Snapper ML
J Am Chem Soc; 2002 Oct; 124(39):11584-5. PubMed ID: 12296709
[TBL] [Abstract][Full Text] [Related]
8. Manoalide: structure-activity studies and definition of the pharmacophore for phospholipase A2 inactivation.
Glaser KB; de Carvalho MS; Jacobs RS; Kernan MR; Faulkner DJ
Mol Pharmacol; 1989 Nov; 36(5):782-8. PubMed ID: 2586492
[TBL] [Abstract][Full Text] [Related]
9. PLA2 inhibitory activity of marine sesterterpenoids cladocorans, their diastereomers and analogues.
Miyaoka H; Yamanishi M; Mitome H
Chem Pharm Bull (Tokyo); 2006 Feb; 54(2):268-70. PubMed ID: 16462082
[TBL] [Abstract][Full Text] [Related]
10. Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation.
Garcia-Pastor P; Randazzo A; Gomez-Paloma L; Alcaraz MJ; Paya M
J Pharmacol Exp Ther; 1999 Apr; 289(1):166-72. PubMed ID: 10087000
[TBL] [Abstract][Full Text] [Related]
11. Scalaradial, a dialdehyde-containing marine metabolite that causes an unexpected noncovalent PLA2 Inactivation.
Monti MC; Casapullo A; Cavasotto CN; Napolitano A; Riccio R
Chembiochem; 2007 Sep; 8(13):1585-91. PubMed ID: 17691073
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of trimethoxyphenyl isoxazolidines as inhibitors of secretory phospholipase A2 with anti-inflammatory activity.
Sadashiva MP; Nataraju A; Mallesha H; Rajesh R; Vishwanath BS; Rangappa KS
Int J Mol Med; 2005 Nov; 16(5):895-904. PubMed ID: 16211261
[TBL] [Abstract][Full Text] [Related]
13. A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration of cacospongionolides.
De Rosa S; Crispino A; De Giulio A; Iodice C; Benrezzouk R; Terencio MC; Ferrándiz ML; Alcaraz MJ; Payá M
J Nat Prod; 1998 Jul; 61(7):931-5. PubMed ID: 9677277
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of phospholipase A2 inhibition by petrosaspongiolide M.
Dal Piaz F; Casapullo A; Randazzo A; Riccio R; Pucci P; Marino G; Gomez-Paloma L
Chembiochem; 2002 Jul; 3(7):664-71. PubMed ID: 12325001
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression.
Guerrero MD; Aquino M; Bruno I; Terencio MC; Paya M; Riccio R; Gomez-Paloma L
J Med Chem; 2007 May; 50(9):2176-84. PubMed ID: 17407277
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of phospholipase A2 by manoalide. Localization of the manoalide binding site on bee venom phospholipase A2.
Glaser KB; Vedvick TS; Jacobs RS
Biochem Pharmacol; 1988 Oct; 37(19):3639-46. PubMed ID: 3178877
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of venom phospholipases A2 by manoalide and manoalogue. Stoichiometry of incorporation.
Reynolds LJ; Mihelich ED; Dennis EA
J Biol Chem; 1991 Sep; 266(25):16512-7. PubMed ID: 1885583
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of manoalide on secreted and intracellular phospholipases.
Bennett CF; Mong S; Clarke MA; Kruse LI; Crooke ST
Biochem Pharmacol; 1987 Mar; 36(5):733-40. PubMed ID: 3103628
[TBL] [Abstract][Full Text] [Related]
19. [Manoalide: a new phospholipase A2 inhibitor of marine origin with potential immunoregulatory effect].
Mayer AM
Medicina (B Aires); 1989; 49(2):175-80. PubMed ID: 2640487
[TBL] [Abstract][Full Text] [Related]
20. Molecular pharmacology of manoalide. Inactivation of bee venom phospholipase A2.
Glaser KB; Jacobs RS
Biochem Pharmacol; 1986 Feb; 35(3):449-53. PubMed ID: 3947381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
